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Background: There is still wide variability in HIV disease course
and other HIV-related outcomes, attributable in part to psychosocial
factors such as major depressive disorder (MDD), a subject that has
received little attention in sub-Saharan Africa.
Methods: Using a longitudinal cohort of 1099 HIV-positive
antiretroviral therapy–naive persons, we investigated the impact of
MDD on 4 HIV-related negative outcome domains in Uganda. MDD
was assessed using a Diagnostic Statistical Manual IV–based tool.
Also collected were data on surrogate measures of the HIV-related
outcome domains. Data were collected at the 3 time points of
baseline, 6, and 12 months. Multiple regression and discrete time
survival models were used to investigate the relationship between
MDD and indices of the HIV outcomes.
Results: MDD was a signiﬁcant predictor of “missed antiretroviral
therapy doses” [adjusted odds ratio (aOR) = 4.75, 95% conﬁdence
interval (CI): 1.87 to 12.04, P = 0.001], “time to ﬁrst visit to healthy
facility” (aOR = 1.71; 95% CI: 1.07 to 2.73; P = 0.024), “time to ﬁrst
self-reported risky sexual activity” (aOR = 2.11, 95% CI: 1.27 to
3.49; P = 0.004) but not of “CD4 counts at months 6 and 12”
(estimated effect 29.0; 95% CI:27.8 to 65.7; P = 0.12), and “time to
new WHO stage 3 or 4 clinical event” (aOR = 0.52, 95% CI: 0.12 to
2.20, P = 0.37).
Conclusions: MDD signiﬁcantly impacted 3 of the 4 investigated
outcome domains. These results by demonstrating the adverse
consequences of an untreated mental health disorder (MDD) on
HIV-related outcomes further strengthen the need to urgently act on
WHO’s call to integrate mental health care in general HIV care.
Key Words: major depressive disorder, HIV outcome measures,
ART adherence, risky sexual behavior, HIV disease progression,
health-seeking behavior, Africa
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BACKGROUND
Depressive disorders are estimated to account for 40%
of the 183$9 million disability-adjusted life years lost
worldwide due to mental and substance use disorders with
more than 80% of this nonfatal disease burden occurring in
low- and middle-income countries.1 HIV/AIDS is one of the
physical disorders associated with depressive disorders with
rates of between 8% and 30% reported in sub-Saharan
African studies.2 Major depressive disorder (MDD) in HIV
not only leads to severe psychological distress, it has been
implicated in the still wide variability observed in HIV
disease course and other related clinical and behavioral
outcomes. In studies largely performed in the west, MDD
has been associated with faster HIV disease progression,3–5
poor drug adherence,6,7 poor health-seeking behavior,8 and
risky sexual behavior.9 Cross-sectional investigation of these
associations is often complicated by the bidirectional causal
relationships and hence the need for longitudinal study
designs.10 To date, only 2 such longitudinal studies have
been undertaken in sub-Saharan Africa, with one study
showing that MDD negatively impacted HIV disease pro-
gression and mortality11 and the other study showing that
MDD negatively impacted risky sexual behavior.12
In addition, understanding the relationship between
MDD- and HIV-related outcomes in a given sociocultural
context has implications for the design of HIV-related clinical
trials and for programmatic development in HIV care. On
clinical trial design, studies in this area will inform which
HIV-related outcomes could be used as secondary outcome
measures in trials that target depression in HIV in a given
sociocultural context. At the programmatic level, such studies
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will inform which psychosocial factors in a given sociocul-
tural context should additionally be targeted to attain
maximum impact against a given set of negative HIV-
related outcomes. In this study, we investigate the impact of
MDD on indices of the 4 HIV-related outcomes of HIV
disease progression, adherence to HIV medications, health-
seeking behavior, and risky sexual behavior using a longitu-
dinal study design in Uganda.
METHODS
Study Design and Site
This was a prospective cohort study conducted in adult
antiretroviral therapy (ART)–naive persons living with HIV
(PLWH) attending at 2 specialized HIV clinics run by The
AIDS Support Organization (TASO) in Uganda.13 Data col-
lection was undertaken at 3 time points: baseline (when
participants undertook their ﬁrst study interview after
enrollment into the study), 6 months after the baseline
assessment, and 12 months after baseline assessment. Initia-
tion of ART was implemented by TASO independently of the
study. At the time of the study, national treatment guidelines
for HIV-infected individuals recommended the initiation of
ART at a CD4 cell count of below 250 cells/mL. In addition,
individuals initiating ART were required to have identiﬁed an
appropriate treatment supporter.
Sampling Procedure
The TASO clinic in Entebbe (semi-urban site) has 7000
active clients of whom about 3000 are ART naïve, whereas
the TASO clinic at Masaka (predominantly rural site) has
6000 active clients of whom about 2500 are not on ART. This
study aimed to enroll 1100 ART-naïve HIV-infected adults
from the 2 clinics. This sample size was chosen to ensure that
the baseline prevalence of MDD would be estimated with
sufﬁcient precision and would also be sufﬁcient to detect
moderate associations between MDD and HIV clinical and
behavioral outcomes. To obtain the required sample from the
2 HIV clinics, a subregister of all active clients who were not
on ART was created. From these subregisters, a random
sample of ART-naïve patients was recruited from each study
clinic using a table of random numbers until a combined total
study sample of 1100 was obtained. About 2% of selected
patients could not be recruited into this study because of any
one of the following reasons: (1) they did not meet eligibility
criteria; nor (2) were already enrolled in another study nor (3)
refused to participate in the study for any other reason.
The inclusion criteria for this study were as follows: (1)
a person living with HIV/AIDS who was ART naïve and
registered with the outpatient clinic at either TASO Entebbe
and TASO Masaka clinics; (2) aged at least 18 years old at
enrollment; and (3) conversant in Luganda, the language in
which the study instruments were translated. Exclusion
criteria were patients who were too sick or unable to
understand the study instruments and those who had missed
their most recent scheduled clinic visit. Eligible participants
were recruited after they had provided written informed
consent after explanation of the study objectives
and procedures.
Data Collection Tools
The data collection tools consisted of structured and
standardized locally translated psychosocial assessment in-
struments, most of which have previously been used among
PLWH in Uganda by this study group.14 Study variables from
these instruments were categorized as follows: sociodemo-
graphic factors: These included study site, sex, age, highest
educational attainment, marital status, religion, occupation,
and socioeconomic index constructed from commonly avail-
able household items in a typical Ugandan households and
previously used by this research group14; exposure variable:
Current MDD, which is the exposure in this study, was
assessed using the Diagnostic Statistical Manual IV–based
MDD module of the Mini International Neuropsychiatric
Interview (M.I.N.I.-Plus), a tool although never formerly
validated in Uganda but has been subject to a formal trans-
lation process and used quite extensively.15 MDD was as-
sessed at each of the 3 time points of baseline, 6 months, and
at 12 months. MDD was reported as a binary outcome with
respondents reported as either having MDD or not having
MDD. A diagnosis of current MDD was made if the
respondent within a time period of not less than 2 weeks met
the following 3 symptom criteria: Criteria 1: must have at
least one of the 2 symptoms (1) or (2): (1) feeling depressed
or down, most of the day, nearly every day; (2) had lost
interest in most things or much less able to enjoy the things
they used to enjoy most of the time; Criteria 2: must have
a total of at least 5 symptoms from the list of (1) to (9),
symptoms (1) and (2) are described under criteria 1, whereas
symptoms (3) to (9) are now described: (3) experienced
weight increase or decrease without trying intentionally; (4)
had trouble sleeping nearly every night; (5) talked or moved
more slowly than normal or were having trouble sitting still
almost every day; (6) feeling tired or without energy almost
every day; (7) feeling worthless or guilty almost every day;
(8) had difﬁculty concentrating or making decisions almost
every day; (9) repeatedly considered hurting yourself, feeling
suicidal, or wishing that you were dead, or attempted suicide
or had a suicide plan; Criteria 3: the above-listed symptoms
should cause signiﬁcant problems at home, at work, socially,
or at school or in some other important way.
Indices of HIV-related outcome measures: data on these
indices were collected at each of the 3 data collection time
points of baseline, 6 months, and 12 months. These indices
were grouped into the following 4 domains, (1) HIV disease
progression (CD4 counts, WHO Clinical Staging criteria16);
(2) health-seeking behavior (number of visits to health
facilities in last month14); (3) adherence to HIV medications
(3-day ART pill count recall14); and (4) risky sexual behavior
(assessed by inquiring about 5 risky sexual behaviors that
have been associated with HIV transmission in the Ugandan
cultural context,17 these questions were, “In the last month,
have you: (1) had sex with anyone other than your regular
partner?; (2) have you had sex in exchange for gifts/money?;
(3) have you had forced sex including rape?; (4) have you
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had sex with someone much older/younger than you?; (5)
have you had sex with someone you had just met?).”
Statistical Analysis
The impact of MDD on the 4 HIV-related outcome
domains was investigated using 5 outcome variables, as
described below:
HIV Disease Progression Domain
i) CD4 count at visit 2 (6 months) and visit 3 (12
months) was one of the outcome variables used to measure
the domain HIV disease progression. The analysis used
a “long” data set, which included for each participant the
CD4 cell count at month 6 and month 12. The primary
exposure, MDD, was lagged, that is, MDD at baseline was
used as the exposure variable for CD4 count at month 6,
whereas MDD at month 6 was used as the exposure for CD4
count at month 12. The reason for lagging MDD was that the
CD4 count at a particular visit was deemed to reﬂect
everything that happened in the previous 6-month period.
Multiple linear regression models were ﬁtted with the use of
robust standard errors to account for the correlation between
CD4 counts within participants. It was felt that 2 observations
per subject were too few to ﬁt linear mixed models for
repeated measurements. The analysis adjusted for study site,
sex, age, visit (ie, month 6 or month 12), and baseline CD4
cell count as explanatory variables. Participants who initiated
ART between baseline and month 6 were excluded, whereas
participants who initiated ART between month 6 and month
12 were included at month 6 but excluded at month 12. The
measure of effect for CD4 count is the difference in CD4 cell
count (cells/mL) between participants with MDD (at the
previous visit) and those without MDD.
ii) Having experienced a WHO stage 3 or 4 event at
month 6 or month 12 was also used to measure the domain
HIV disease progression. The time to the ﬁrst WHO stage 3 or
4 event was analyzed using discrete time survival models.18,19
Discrete time survival models were used to investigate the
time (6 months or 12 months) to the ﬁrst WHO stage 3 or 4
event. In practice, this is performed by ﬁtting logistic
regression models, so although the derivation is based on
the hazard (risk of an event at the given visit), the parameters
of the model can be interpreted as odds ratios. The primary
exposure, MDD, was lagged, that is, MDD at baseline was
used as the exposure variable for a WHO stage 3 or 4 event at
month 6, whereas MDD at month 6 was used as the exposure
for a WHO stage 3 or 4 event at month 12. The analysis
adjusted for study site, sex, age, visit (ie, month 6 or month
12), and baseline CD4 cell count as explanatory variables.
Participants who initiated ART before month 6 were
excluded, whereas those who initiated ART between month
6 and month 12 were included at month 6 but excluded at
month 12. Participants who had already experienced a WHO
stage 3 or 4 event at baseline were also excluded from the
analysis. The measure of effect is the (adjusted) odds ratio for
a WHO stage 3 or 4 event for participants with MDD (at the
previous visit) compared with those without MDD.
Adherence to HIV Medications Domain
iii) Having missed at least one dose of ART medica-
tions in the 3 days before the interview was used as a measure
for the domain on adherence to HIV medication. Missing at
least one dose of ART at month 6 and month 12 was analyzed
by ﬁtting a multiple logistic regression model to a “long” data
set with up to 2 observations per participant; robust standard
errors were used to account for the correlation of responses
within participants. In this case, the primary exposure (MDD)
was not lagged, since the MDD was evaluated over the 2
weeks before the visit and missing at least one dose of ART
was evaluated over the 3 days before the visit, so we assumed
that the exposure (MDD) preceded the outcome (missing at
least one dose of ART). The analysis adjusted for study site,
sex, age, visit (ie, month 6 or month 12), and baseline CD4
cell count as explanatory variables. The analysis was
restricted to participants who initiated ART between baseline
and month 6 (who were included at month 6 and month 12)
and participants who initiated ART between month 6 and
month 12 (who were included at month 12 only). The
measure of effect is the (adjusted) odds ratio for missing at
least one dose of ART for participants with MDD compared
with those without MDD.
Health-Seeking Behavior Domain
(iv) The time to the ﬁrst visit to a health facility was
used as a measure of health-seeking behavior and was
analyzed using discrete time survival models. The primary
exposure, MDD, was lagged, that is, MDD at baseline was
used as the exposure variable for a visit to a health facility at
month 6, whereas MDD at month 6 was used as the exposure
variable for a visit to a health facility at month 12. The
analysis adjusted for study site, sex, age, visit (ie, month 6 or
month 12), and baseline CD4 cell count as explanatory
variables. Participants who had their ﬁrst visit to a health
facility at baseline were excluded from the analysis, whereas
those who visited a health facility between month 6 and
month 12 were included at month 6 but excluded at month 12.
The measure of effect is the (adjusted) odds ratio for a visit to
a health facility for participants with MDD (at the previous
visit) compared with those without MDD.
Risky Sexual Behavior Domain
v) Having engaged in risky sexual behavior (as
measured by at least one afﬁrmative answer to the 5 questions
on sexual behavior) was analyzed using discrete time survival
models. The primary exposure (MDD) was lagged. The
analysis adjusted for study site, sex, age, visit, and baseline
CD4 count as explanatory variables. Participants who had
engaged in risky sexual behavior at baseline were excluded
from the analysis, whereas those who engaged in risky sexual
behavior at month 6 were excluded at month 12. The measure
of effect is the (adjusted) odds ratio for risky sexual behavior
for participants with MDD (at the previous visit) compared
with those without MDD.
We did not adjust for multiple signiﬁcance testing.
Although this increases the chance of type I errors, the aim of
the analysis was to identify potentially detrimental conse-
quences of MDD, which can be seen as analogous to safety
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TABLE 1. Sociodemographics, Psychosocial Exposures, and HIV-Related Outcomes of the Study Population by Data Collection
Time Period
Factor Level Baseline Month 6 Month 12
Overall 1099 1059 1041
Sociodemographics
Study site Entebbe 542 (49.3%) 520 (49.1%) 509 (48.9%)
Masaka 557 (50.7%) 539 (50.9%) 532 (51.1%)
Sex Male 252 (22.9%) 243 (23.0%) 238 (22.9%)
Female 847 (77.1%) 816 (77.0%) 803 (77.1%)
Age Mean (SD) 35.1 (9.3) 35.1 (9.3) 35.1 (9.1)
Median (IQR) 34 (28–41) 34 (28–41) 34 (28–41)
Age (grouped) 18–29 339 (30.8%) 321 (30.3%) 316 (30.4%)
30–34 252 (22.9%) 248 (23.4%) 244 (23.4%)
35–39 197 (17.9%) 188 (17.8%) 185 (17.8%)
40–49 225 (20.5%) 218 (20.6%) 216 (20.8%)
$50 86 (7.8%) 84 (7.9%) 80 (7.7%)
Education status None 120 (10.9%) 113 (10.7%) 113 (10.8%)
Primary 680 (61.9%) 654 (61.8%) 641 (61.6%)
Secondary or more 296 (26.9%) 289 (27.3%) 284 (27.3%)
Missing 3 (0.3%) 3 (0.3%) 3 (0.3%)
Marital status Currently married 563 (51.2%) 540 (51.0%) 533 (51.2%)
Widowed 163 (14.8%) 157 (14.8%) 158 (15.2%)
Separated/divorced 267 (24.3%) 261 (24.6%) 254 (24.4%)
Single 104 (9.5%) 99 (9.4%) 94 (9.0%)
Missing 2 (0.2%) 2 (0.2%) 2 (0.2%)
Religion Catholic 586 (53.3%) 566 (53.4%) 562 (54.0%)
Protestant 237 (21.6%) 228 (21.5%) 224 (21.5%)
Muslim 163 (14.8%) 158 (14.9%) 152 (14.6%)
Seventh day 16 (1.5%) 16 (1.5%) 14 (1.3%)
Born again 93 (8.5%) 87 (8.2%) 85 (8.2%)
Other 4 (0.4%) 4 (0.4%) 4 (0.4%)
Occupation Farmer/ﬁshing 324 (29.5%) 321 (30.3%) 310 (29.8%)
Professional/clerical 43 (3.9%) 42 (4.0%) 42 (4.0%)
Trader/artisan/transport 396 (36.0%) 386 (36.4%) 383 (36.8%)
Unemployed/retired 139 (12.6%) 126 (11.9%) 126 (12.1%)
housewife 187 (17.0%) 174 (16.4%) 172 (16.5%)
Student/other 10 (0.9%) 10 (0.9%) 8 (0.8%)
SES index Mean (SD) 15.1 (3.6) 15.1 (3.6) 15.1 (3.6)
Median (IQR) 15 (13–17) 15 (13–17) 15 (13–17)
Psychosocial exposures
Current MDD No 944 (85.9%) 991 (93.6%) 987 (94.8%)
Yes 155 (14.1%) 59 (5.6%) 44 (4.2%)
Missing 0 9 (0.8%) 10 (1.0%)
HIV-related outcomes
CD4 count Mean (SD) 516.2 (267.6) 560.6 (235.4) 600.6 (233.4)
Median (IQR) 471 (352; 665) 517 (407; 687) 556 (435; 711)
Geometric mean (95% CI) 430.7 (412 to 450) 514.6 (498 to 532) 516.1 (497 to 537)
WHO stage I 533 (48.5%) 308 (45.4%) 233 (43.3%)
II 500 (45.5%) 347 (51.2%) 265 (49.3%)
III/IV 66 (6.0%) 23 (3.4%) 25 (4.6%)
Missing 0 0 15 (2.8%)
Missed a dose of ART in past 3 days No 289 (86.8%) 390 (83.3%)
Yes 30 (9.0%) 31 (6.6%)
N/A 14 (4.2%) 47 (10.0%)
(continued on next page)
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analysis in drug trials in which the aim is to identify potential
risks caused by the investigational drug, in which case
adjusting for multiplicity is not recommended.20
Ethical Considerations
The study obtained ethical approval from the Uganda
Virus Research Institute’s Science and Ethics Committee and
the Uganda National Council of Science and Technology.
Study participants were invited to consent and participate in
this study by trained psychiatric nurses after being provided
with adequate information about the study. Respondents
found to have signiﬁcant psychiatric problems were referred
to psychiatric departments nearest to their study sites for
further assessment and management.
RESULTS
Overall retention in the study at one year was high, with
1041 (94.7%) of participants seen at month 12. Of the 1099
participants assessed at baseline, 67 (6.2%) were lost to
follow-up by 12 months, of whom 18 were conﬁrmed to have
died during the course of this study, the majority due to non–
HIV-related causes. None of the factors of study site, sex,
marital status, and baseline MDD were associated with loss to
follow-up. In this study, missing data of not more than 1%
were recorded on the variables educational status, marital
status, current MDD, visits to health facilities in the past
month, and any risky sexual activity. It was only on the
variable WHO stage that missing data of 2.8% were recorded
at the 12-month data collection time point (Table 1
for details).
Sociodemographic Factors, Psychosocial
Exposure, and HIV-Related Outcomes
A summary of sociodemographic data, psychosocial
exposure variable, and clinical and behavioral outcomes are
given in Table 1. A detailed description of the characteristics
of this study population can be found in earlier publica-
tions.2,21 The number of participants at the 2 study sites was
similar throughout the 3 reporting periods (baseline, 6
months, and 12 months). Overall, just over three-quarter of
participants were women and the mean age overall was 35
years. Only 296 (27%) of participants had secondary or
higher education. About half of the participants were
currently married, with less than 104 (10%) having never
been married. The proportion of respondents with a current
episode of MDD decreased from 155 (14%) at baseline to 59
(5.6%) at month 6 and to a further 44 (4.2%) at month 12.
In this study, CD4 cell counts showed large variability,
both between participants and between periods within
participants. The CD4 count increased over time; this increase
can be partly explained by the fact that participants who
started ART, and who had the lowest CD4 counts, were
excluded from the subsequent analysis of CD4 counts. The
baseline CD4 counts were based on 1099 participants,
whereas at month 6, the CD4 counts were based on 694
participants who had not yet started ART, and at month 12,
the CD4 counts were based on 547 participants who had not
yet started ART. Few participants experienced a new WHO
stage 3 or 4 event, 6% at baseline, of those without a baseline
event, 3.4% at month 6, and of the remainder 4.6% at
month 12.
Associations Between the MDD and HIV
Clinical and Behavioral Outcomes
Given below are the results of ﬁtting models to ﬁnd
associations between MDD- and HIV-related clinical and
behavioral outcomes.
Model for CD4 Counts
The analysis of the CD4 count by ﬁtting a linear
regression model, with the use of robust variance estimation
to adjust for the within-subject correlation at month 6 and
month 12, was based on 694 participants at month 6 and 547
participants at month 12; participants were excluded from this
analysis if they had initiated ART before the visit concerned.
The results of ﬁtting the linear regression model with robust
variance estimators are summarized in Table 2. MDD was not
signiﬁcantly associated with the CD4 count at the follow-up
visits, adjusting for study site, sex, age, and baseline CD4
count. The estimated effect showed that participants with
MDD had higher CD4 counts on average, but the difference
TABLE 1. (Continued ) Sociodemographics, Psychosocial Exposures, and HIV-Related Outcomes of the Study Population by Data
Collection Time Period
Factor Level Baseline Month 6 Month 12
Visits to health facility in past month None 781 (71.1%) 603 (80.1%) 507 (86.7%)
Once 146 (13.3%) 70 (9.3%) 47 (8.0%)
Twice 85 (7.7%) 45 (6.0%) 18 (3.1%)
Three or more 86 (7.8%) 31 (4.1%) 10 (1.7%)
Missing 1 (0.1%) 4 (0.5%) 3 (0.5%)
Any risky sexual activity No 950 (86.4%) 832 (91.0%) 737 (90.9%)
Yes 149 (13.6%) 74 (8.1%) 66 (8.1%)
Missing 0 8 (0.9%) 8 (1.0%)
IQR, interquartile range; SES, socioeconomic.
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was not statistically signiﬁcant (estimated effect 29.0; 95%
CI: 27.8 to 65.7; P = 0.12).
Model for Time to First New WHO Stage 3 or
4 Event
The analysis of the time to the ﬁrst new WHO stage 3
or 4 event using a discrete time survival model was based on
706 participants, with 333 participants excluded because of
initiating ART and 28 participants excluded, as they had
experienced a WHO stage 3 or 4 event at baseline. In total, 24
participants experienced a WHO stage 3 or 4 event at month 6
and a further 25 participants experienced a WHO stage 3 or 4
event at month 12. The results of ﬁtting the discrete time
survival model are summarized in Table 3. MDD was not
signiﬁcantly associated with the odds of experiencing a WHO
stage 3 or 4 event, adjusting for study site, sex, age, and
baseline CD4 count [adjusted odds ratio (aOR) = 0.52; 95%
conﬁdence interval (CI): 0.12 to 2.20; P = 0.37].
Model for Having Missed a Dose of ART
The analysis of having missed at least one dose of ART
was based on 468 participants of whom 333 had initiated
ART by month 6. At month 6, 30/333 participants missed at
least one dose of ART in the 3 days before the visit, whereas
at month 12, 31/468 participants missed at least one dose of
ART. The results of ﬁtting a logistic regression model with
robust variance estimators are summarized in Table 4.
Adjusting for study site, sex, age, and baseline CD4 count,
the odds of having missed at least one dose of ART were 4.75
times as high for participants with MDD compared with those
without MDD (aOR = 4.75; 95% CI: 1.87 to 12.04; P
= 0.001).
Model for Having Visited a Health Facility
The analysis of the time to the ﬁrst visit to a health
facility using a discrete time survival model was based on 763
participants; the 309 participants who had visited a health
facility at baseline were excluded from the analysis. In total,
146 participants visited a health facility in the month before
visit 2 (month 6) and a further 77 participants visited a health
facility in the month before visit 3 (month 12). The results of
ﬁtting a discrete time survival model are summarized in Table
5. Adjusting for study site, sex, age, and baseline CD4 count,
the odds of having undertaken a visit to the health facility
were 1.71 times as high for participants with MDD (at the
previous visit) compared with those without MDD (aOR =
1.71; 95% CI: 1.07 to 2.73; P = 0.024).
Model for Any Risky Sexual Behavior
The analysis of the time to the ﬁrst self-reported risky
sexual behavior using a discrete time survival model was
based on 906 participants; 147 participants were excluded as
they reported having engaged in risky sexual behavior at
baseline, whereas 20 participants had missing responses to all
5 questions at month 6 and 36 participants had missing
responses to all 5 questions at month 12. In total, 74
participants reported in having engaged in risky sexual
behavior at month 6 and a further 67 reported having engaged
TABLE 2. Results of Fitting Models to Outcomes Associated
With MDD: Multiple Linear Regression With Robust Variance
Estimation for CD4 Counts
Factor Level
Effect (Robust 95%
CI) P
Study site Entebbe 0 (reference) ,0.001
Masaka 53.8 (28.3 to 79.4)
Sex Male 0 (reference) 0.024
Female 33.8 (4.5 to 63.1)
Age Per 10-year
increase
29.5 (223.0 to 4.1) 0.17
Visit Visit 2 (month 6) 0 (reference) ,0.001
Visit 3 (month 12) 23.6 (6.4 to 40.9)
Baseline CD4
count
Per unit increase 0.56 (0.49 to 0.63) ,0.001
MDD (lagged) No 0 (reference) 0.12
Yes 29.0 (27.8 to 65.7)
TABLE 3. Results of Fitting Models to Outcomes Associated
With MDD: Discrete Time Survival Model for Time to WHO
Stage 3 or 4 Event
Factor Level
Adjusted Odds Ratio
(95% CI) P
Study site Entebbe 1 (reference) ,0.001
Masaka 0.30 (0.16 to 0.57)
Sex Male 0 (reference) 0.68
Female 1.17 (0.56 to 2.47)
Age Per 10-year
increase
1.16 (0.85 to 1.58) 0.35
Visit Visit 2 (month 6) 1 (reference) 0.26
Visit 3 (month 12) 1.40 (0.78 to 2.51)
Baseline CD4
count
Per 100-cell/mL
increase
1.004 (0.89 to 1.13) 0.95
MDD (lagged) No 1 (reference) 0.12
Yes 0.52 (0.12 to 2.20)
TABLE 4. Results of Fitting Models to Outcomes Associated
With MDD: Logistic Regression Model With Robust Variance
for Missing ART
Factor Level
Adjusted Odds Ratio (Robust
95% CI) P
Study site Entebbe 1 (reference) 0.007
Masaka 0.36 (0.17 to 0.76)
Sex Male 0 (reference) 0.52
Female 0.83 (0.47 to 1.47)
Age Per 10-year
increase
0.98 (0.72 to 1.33) 0.90
Visit Visit 2 (month 6) 1 (reference) 0.38
Visit 3 (month 12) 0.79 (0.48 to 1.32)
Baseline CD4
count
Per 100-cell/mL
increase
0.94 (0.79 to 1.11) 0.45
MDD (lagged) No 1 (reference) 0.001
Yes 4.75 (1.87 to 12.04)
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in risky sexual behavior at month 12. The results of ﬁtting
a discrete time survival model are summarized in Table 6.
Adjusting for study site, sex, age, and baseline CD4 count,
the odds of having engaged in risky sexual behavior were
2.11 times as high for participants with MDD (at the previous
visit) compared with those without MDD (aOR = 2.11; 95%
CI: 1.27 to 3.49; P = 0.004).
DISCUSSION
This, to our knowledge, is only the third article from
sub-Saharan Africa that has investigated the association
between MDD and HIV-related negative outcomes using
a prospective study design to control for possible bidirection-
ality.10 Although each of the 2 earlier studies only looked at
the relationship between MDD and one HIV-related out-
come,11,12 this study investigated the relationship between
MDD and indices of the 4 HIV-related outcome domains of
HIV disease progression, adherence to HIV medications,
health-seeking behavior and risky sexual behavior.
Two indices were used to assess HIV disease pro-
gression in this study, namely, CD4 counts at 6 and 12
months and time to the ﬁrst new WHO stage 3 or 4 event. In
this study, we found no evidence that MDD at the previous
visit was associated with either of these 2 indices used to
assess for HIV disease progression. In the literature there are
conﬂicting results on the association between MDD and HIV
disease progression with some systematic reviews and meta-
analyses reporting a signiﬁcant association4 while others do
not report such a ﬁnding.22 Possible explanations for these
conﬂicting results include the complexity of the relationship
between neuropsychiatric disorders such as MDD and the
immune system in HIV/AIDS23,24 and methodological issues
including differences in study design and choice of HIV
disease progression indicators4 and the high variability of
some indices used as a surrogate measure of HIV disease
progression.24 Indeed, the relationship between MDD and
CD4 counts in this study could have been confounded by the
wide variability shown by CD4 counts both between subjects
and between time periods within subjects.
In this study, we found that MDD at the current visit
was associated with nearly a ﬁve-fold increase in the odds of
missing at least one dose of ART in the previous 3 days.
Although we feel this was a fairly robust ﬁnding, it is
important to note that there were smaller numbers on ART
compared with the cohort as a whole. In line with these
ﬁndings, 2 previous systematic reviews have reported that
depression negatively impacted ART adherence.6,25 On
health-seeking behavior, our ﬁndings were that having a pre-
vious episode of MDD was associated with a nearly two-fold
increased risk of visiting a health facility. Although previous
studies have reported MDD as a predictor of poor access to
general HIV care services,8 a multisite European study
reported increased utilization of psychiatric services by
individuals with MDD in the community.26 The increased
utilization of HIV care services that were associated with
MDD in this study may have been a “cry for help” from
persons experiencing psychological distress whose needs
were not being met by an HIV care system that is not yet
responsive to the mental health needs of PLWH. We did not
control for distance between the respondent’s home and the
HIV clinic, a variable that could have confounded the
above relationship.
We observed that MDD was associated with a two-fold
increased risk of engaging in risky sexual behavior. Both Seth
et al9 among female African American adolescents in the
United States of America and Nduna et al12 among young
adults in South Africa have reported MDD as a signiﬁcant
predictor of risky sexual behavior.
In conclusion, this study has demonstrated that MDD
signiﬁcantly impacted the HIV-related outcome domains of
adherence to HIV medications, health-seeking behavior, and
risky sexual behavior but not of HIV disease progression.
These results add further weight to the recent recommenda-
tion by the WHO to integrate mental health into HIV care
services27 by demonstrating the adverse consequences of an
untreated mental health disorder (MDD) on HIV-related
clinical and behavioral outcomes. In addition, these results
support an observation made by Collins et al28 who in
TABLE 5. Results of Fitting Models to Outcomes Associated
With MDD: Discrete Time Survival Model for Time to Visit to
Health Facility
Factor Level
Adjusted Odds Ratio
(95% CI) P
Study site Entebbe 1 (reference) ,0.001
Masaka 3.23 (2.33 to 4.49)
Sex Male 0 (reference) 0.23
Female 1.26 (0.86 to 1.85)
Age Per 10-year
increase
1.02 (0.86 to 1.20) 0.82
Visit Visit 2 (month 6) 1 (reference) 0.015
Visit 3 (month 12) 0.68 (0.49 to 0.93)
Baseline CD4
count
Per 100-cell/mL
increase
0.97 (0.91 to 1.02) 0.23
MDD (lagged) No 1 (reference) 0.024
Yes 1.71 (1.07 to 2.73)
TABLE 6. Results of Fitting Models to Outcomes Associated
With MDD: Discrete Time Survival Model for Time to First
Risky Sexual Behavior
Factor Level
Adjusted Odds Ratio
(95% CI) P
Study site Entebbe 1 (reference) 0.25
Masaka 0.81 (0.56 to 1.16)
Sex Male 0 (reference) 0.003
Female 0.55 (0.37 to 0.81)
Age Per 10-year increase 0.71 (0.57 to 0.88) 0.002
Visit Visit 2 (month 6) 1 (reference) 0.64
Visit 3 (month 12) 1.09 (0.76 to 1.55)
Baseline CD4
count
Per 100-cell/mL
increase
0.98 (0.92 to 1.05) 0.61
MDD (lagged) No 1 (reference) 0.004
Yes 2.11 (1.27 to 3.49)
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a systematic review on the relevance of mental health to HIV/
AIDS care and treatment programs in developing countries
noted that behavioral factors including mental health disor-
ders are likely to be a major determinant in ART roll. In
response to this observation, Collins et al (2006) then called
for methodologically sound studies, such as this one, that
among others describe the mental health–related predictors of
ART adherence. Finally, these results suggest that, in the sub-
Saharan African setting of Uganda, psychosocial factors such
as MDD should among others be targeted in the design of
interventions to address the HIV outcomes of adherence to
HIV medications, health-seeking behavior, and risky sexual
behavior. There is however a need for more studies to further
validate these ﬁndings in this sociocultural context.
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